MYCN and neuroblastoma: In NB, recurrent large genomic alterations such as MYCN amplification, 1p and 11q deletions, unbalanced 17q gain [2], TERT rearrangements [3] and 19p loss [4] are reliable predictors of poor clinical outcome.